Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hyperprolactinemia
Comorbidity C0001430|adenoma
Sentences 3
PubMedID- 20963563 Patients were divided into three groups according to treatment outcomes and pathologic results: (a) prolactinoma that responded to dopamine agonist (da) treatment (prda); (b) prolactinoma requiring surgical treatment (prs); and (c) non-functioning pituitary adenoma with hyperprolactinemia (nfpah).
PubMedID- 22418404 hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy.
PubMedID- 22838183 Pathological hyperprolactinemia may result from a lactotroph adenoma (prolactinoma), empty sella syndrome, intracranial tumors compressing the pituitary stalk or hypothalamus, dopamine receptor d2 antagonist and prl stimulative drugs, repetitive mechanical stimulation of breast, chest wall trauma, hepatorenal disease and primary hypothyroidism (4–6).

Page: 1